ATXS Astria Therapeutics, Inc.

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.

$5.08
As of 12/03/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/25/2015
Outstanding shares:  13,009,477
Average volume:  47,358
Market cap:   $66,348,333
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    04635X102
ISIN:        US04635X1028
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.94
PS ratio:   0.00
Return on equity:   -25.53%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy